BINEX Past Earnings Performance
Past criteria checks 0/6
BINEX's earnings have been declining at an average annual rate of -52.3%, while the Pharmaceuticals industry saw earnings growing at 3.7% annually. Revenues have been growing at an average rate of 2% per year.
Key information
-52.34%
Earnings growth rate
-52.27%
EPS growth rate
Pharmaceuticals Industry Growth | 11.32% |
Revenue growth rate | 1.96% |
Return on equity | -13.73% |
Net Margin | -18.05% |
Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Would BINEX (KOSDAQ:053030) Be Better Off With Less Debt?
May 15What You Can Learn From BINEX Co., Ltd.'s (KOSDAQ:053030) P/S After Its 25% Share Price Crash
Mar 05Here's Why BINEX (KOSDAQ:053030) Can Afford Some Debt
Feb 13Revenues Tell The Story For BINEX Co., Ltd. (KOSDAQ:053030) As Its Stock Soars 35%
Jan 08BINEX Co., Ltd. (KOSDAQ:053030) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Nov 18Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?
Oct 23Revenues Not Telling The Story For BINEX Co., Ltd. (KOSDAQ:053030) After Shares Rise 25%
Sep 01Subdued Growth No Barrier To BINEX Co., Ltd. (KOSDAQ:053030) With Shares Advancing 32%
Jul 01BINEX Co., Ltd.'s (KOSDAQ:053030) 30% Share Price Plunge Could Signal Some Risk
Apr 17We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish Earnings
Mar 22BINEX Co., Ltd.'s (KOSDAQ:053030) Shares Climb 37% But Its Business Is Yet to Catch Up
Feb 26Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?
Mar 18If You Had Bought BINEX (KOSDAQ:053030) Stock A Year Ago, You Could Pocket A 253% Gain Today
Jan 28Are BINEX Co., Ltd.'s (KOSDAQ:053030) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Dec 24Revenue & Expenses Breakdown
How BINEX makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 25 | 140,128 | -25,287 | 48,166 | 1,261 |
31 Dec 24 | 130,051 | -35,071 | 49,911 | 1,201 |
30 Sep 24 | 129,614 | -25,172 | 50,055 | 1,184 |
30 Jun 24 | 128,302 | -18,860 | 50,895 | 1,328 |
31 Mar 24 | 136,335 | -12,165 | 51,956 | 1,255 |
31 Dec 23 | 154,825 | 4,671 | 53,805 | 1,310 |
30 Sep 23 | 160,785 | 2,845 | 56,346 | 2,246 |
30 Jun 23 | 168,715 | 13,451 | 55,821 | 1,928 |
31 Mar 23 | 169,566 | 17,625 | 53,973 | 1,821 |
31 Dec 22 | 156,677 | 12,445 | 50,866 | 1,618 |
30 Sep 22 | 154,969 | 16,511 | 48,513 | -153 |
30 Jun 22 | 148,847 | 16,354 | 46,793 | 5 |
31 Mar 22 | 137,081 | 12,565 | 46,070 | 181 |
31 Dec 21 | 134,399 | 19,094 | 45,916 | 384 |
30 Sep 21 | 129,474 | 10,144 | 45,087 | 1,174 |
30 Jun 21 | 129,031 | 9,390 | 45,622 | 1,157 |
31 Mar 21 | 134,424 | 13,278 | 44,277 | 1,112 |
31 Dec 20 | 132,976 | 6,412 | 44,486 | 1,097 |
30 Sep 20 | 131,550 | 13,970 | 43,387 | 1,104 |
30 Jun 20 | 129,097 | 11,463 | 42,953 | 1,121 |
31 Mar 20 | 127,064 | 8,735 | 43,956 | 1,092 |
31 Dec 19 | 125,259 | 8,504 | 43,179 | 1,035 |
30 Sep 19 | 122,942 | 13,092 | 40,635 | 1,009 |
30 Jun 19 | 119,099 | 13,565 | 40,408 | 1,000 |
31 Mar 19 | 111,203 | 8,878 | 40,394 | 945 |
31 Dec 18 | 104,043 | 6,337 | 39,297 | 895 |
30 Sep 18 | 91,167 | -4,232 | 40,651 | 785 |
30 Jun 18 | 84,136 | -9,325 | 39,074 | 658 |
31 Mar 18 | 79,031 | -12,419 | 35,551 | 660 |
31 Dec 17 | 78,026 | -10,797 | 34,419 | 622 |
30 Jun 17 | 80,782 | -7,528 | 30,512 | 704 |
31 Mar 17 | 81,500 | -3,065 | 29,823 | 761 |
31 Dec 16 | 80,924 | -3,144 | 29,053 | 818 |
30 Sep 16 | 77,576 | -12,169 | 29,469 | 885 |
30 Jun 16 | 74,890 | -10,196 | 27,535 | 956 |
31 Mar 16 | 71,804 | -9,553 | 26,417 | 1,043 |
31 Dec 15 | 66,539 | -9,289 | 24,324 | 1,169 |
30 Sep 14 | 56,724 | -2,357 | 21,231 | 1,404 |
30 Jun 14 | 58,746 | -3,158 | 21,328 | 1,682 |
Quality Earnings: A053030 is currently unprofitable.
Growing Profit Margin: A053030 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A053030 is unprofitable, and losses have increased over the past 5 years at a rate of 52.3% per year.
Accelerating Growth: Unable to compare A053030's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A053030 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-11.6%).
Return on Equity
High ROE: A053030 has a negative Return on Equity (-13.73%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/28 23:01 |
End of Day Share Price | 2025/05/28 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BINEX Co., Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Heeyoung Lee | Daishin Securities Co. Ltd. |
Sang-Hun Lee | iM Securities |
Sung Hwan Choi | Kyobo Securities Co., Ltd |